Answers are grounded in this paper and cite their sources.
T lymphocytes accumulate after treatment in both arms. A low ROR score is observed at surgery in 63.3% and 43.5% of patients in the LP and CT arms, respectively. No 3-year breast cancer-specific survival events are observed in these patients. These data provide a rationale for CT-sparing trials in this setting.
No takes yet. Share an insight, caveat, or question.
Cottu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: